The data add to growing evidence supporting the use of HER2 therapy across solid tumors, though researchers find a difficult path to a tissue-agnostic approval.
Tempus Labs researchers said they could match more than 40 percent of patients to a targeted treatment and 77 percent of patients to a relevant clinical trial.
Researchers identified tumor microbe and immune differences in tumor samples from pancreatic ductal adenocarcinoma patients with exceptionally long survival.
The TATTON study found a combination therapy could treat some EGFR-positive lung cancer patients who developed MET-based resistance, but the best way to gauge MET status isn't yet clear.
Researchers identified characteristic alterations, immune features, and interactions in hundreds of adenocarcinoma and squamous cell carcinomas from China.
Based on the findings, MD Anderson is already using HER2 status to recommend patients for clinical trials instead of EGFR drugs and authors recommend others follow suit.
Using samples from different points in patients' treatment, researchers employed a variety of tools, including NanoString's GeoMx DSP, to explore potential response markers.
A PCR-based analysis of nearly 700 cases picked up human papillomavirus or human polyomaviruses DNA in a fraction of urothelial bladder carcinoma tumors.
In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.
